685 related articles for article (PubMed ID: 23656643)
21. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
[No Abstract] [Full Text] [Related]
22. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
23. Current Management of Chronic Neutrophilic Leukemia.
Szuber N; Tefferi A
Curr Treat Options Oncol; 2021 Jun; 22(7):59. PubMed ID: 34097138
[TBL] [Abstract][Full Text] [Related]
24. T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form.
Price A; Druhan LJ; Lance A; Clark G; Vestal CG; Zhang Q; Foureau D; Parsons J; Hamilton A; Steuerwald NM; Avalos BR
Biochem Biophys Res Commun; 2020 Feb; 523(1):208-213. PubMed ID: 31848046
[TBL] [Abstract][Full Text] [Related]
25. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
26. Leukemia Cell Lines: In Vitro Models for the Study of Chronic Neutrophilic Leukemia.
Drexler HG; Nagel S; Quentmeier H
Curr Oncol; 2021 May; 28(3):1790-1794. PubMed ID: 34068566
[TBL] [Abstract][Full Text] [Related]
27. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
[TBL] [Abstract][Full Text] [Related]
28. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
29. Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.
Carratt SA; Brewer D; Maxson JE; Druker BJ; Braun TP
Biomark Res; 2021 Jan; 9(1):8. PubMed ID: 33516272
[TBL] [Abstract][Full Text] [Related]
30. A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.
Spiciarich DR; Oh ST; Foley A; Hughes SB; Mauro MJ; Abdel-Wahab O; Press RD; Viner R; Thompson SL; Chen Q; Azadi P; Bertozzi CR; Maxson JE
Cancer Res; 2018 Dec; 78(24):6762-6770. PubMed ID: 30348809
[TBL] [Abstract][Full Text] [Related]
31. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
[TBL] [Abstract][Full Text] [Related]
32. A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications.
Mitsumori T; Komatsu N; Kirito K
Intern Med; 2016; 55(4):405-7. PubMed ID: 26875968
[TBL] [Abstract][Full Text] [Related]
33. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
35. [CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].
Cui Y; Li B; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1069-73. PubMed ID: 25543699
[TBL] [Abstract][Full Text] [Related]
36. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
37. Genetically informed therapy in leukemia.
Radich J
N Engl J Med; 2013 May; 368(19):1838-9. PubMed ID: 23656651
[No Abstract] [Full Text] [Related]
38. Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management.
Elliott MA; Tefferi A
Am J Hematol; 2014 Jun; 89(6):651-8. PubMed ID: 24845374
[TBL] [Abstract][Full Text] [Related]
39. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
